Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of s (Q83499656)
Jump to navigation
Jump to search
scientific article published on 01 March 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of s |
scientific article published on 01 March 2011 |
Statements
Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year (English)
Joel M Kremer
Ruben Burgos-Vargas
Anne-Marie Halland
Emma Vernon
Petra Ambs
Roy Fleischmann